The present disclosure relates to a method of producing lactic acid bacteria dual-coated with protein and polysaccharide by using a protein hydrolysate, and lactic acid bacteria having a dual coating, produced by the method. The lactic acid bacteria having a dual coating of protein and polysaccharide, produced according to the present disclosure, have very excellent dry-freezing viability, acid resistance and bile resistance. Accordingly, the lactic acid bacteria having a dual coating of protein and polysaccharide according to the present disclosure will be very useful for the production of fermented milk, processed milk, fermented soy products, processed foods, functional beverages, functional foods, common foods, etc.

A method for producing -aminobutyric acid includes cultivating, in a culture medium containing glutamic acid or a salt thereof, a probiotic composition including at least one lactic acid bacterial strain selected from the group consisting of Bifidobacterium breve CCFM1025 which is deposited at the Guangdong Microbial Culture Collection Center under an accession number GDMCC 60386, Lactobacillus acidophilus TYCA06, Lactobacillus plantarum LPL28, and Bifidobacterium longum subsp. infantis BLI-02 which are deposited at the China General Microbiological Culture Collection Center respectively under accession numbers CGMCC 15210, CGMCC 17954, and CGMCC 15212, Lactobacillus salivarius subsp. salicinius AP-32 which is deposited at the China Center for Type Culture Collection under an accession number CCTCC M 2011127, and combinations thereof.

A digestive product includes a probiotic component and an immune modulator, such as transfer factor and/or a nanofraction immune modulator. The digestive product may also contain a prebiotic component, such as one or more of galactooligosaccharides, xylooligosaccharides, and fructooligosaccharides. The probiotic component may be encapsulated, such as probiotic micro beadlets.

Provided is a composition for preventing or ameliorating a functional gastrointestinal disorder whose active ingredient is Bifidobacterium breve MCC1274 (FERM BP-11175). A composition for preventing or ameliorating a functional gastrointestinal disorder in the present technology can prevent or improve constipation or frequent bowel movements, regulate the number of bowel movements, improve stool quality, prevent or improve constipation, prevent or ameliorate bloating, or prevent or improve abdominal discomfort. Disclosed is a composition for preventing or ameliorating a functional gastrointestinal disorder accompanied by anxiety disorder. A composition for preventing or ameliorating a functional gastrointestinal disorder in the present technology can be used in a pharmaceutical composition or in a food or beverage composition.

Provided is a composition for preventing or ameliorating a functional gastrointestinal disorder whose active ingredient is Bifidobacterium breve MCC1274 (FERM BP-11175). A composition for preventing or ameliorating a functional gastrointestinal disorder in the present technology can prevent or improve constipation or frequent bowel movements, regulate the number of bowel movements, improve stool quality, prevent or improve constipation, prevent or ameliorate bloating, or prevent or improve abdominal discomfort. Disclosed is a composition for preventing or ameliorating a functional gastrointestinal disorder accompanied by anxiety disorder. A composition for preventing or ameliorating a functional gastrointestinal disorder in the present technology can be used in a pharmaceutical composition or in a food or beverage composition.

A composition for relieving stress comprising a Bifidobacterium breve MCC 1274 (FERMBP-11175) as an active ingredient is provided. The composition for relieving stress according to the present technology can improve or prevent stress-induced anger, confusion, tension, or fatigue, or can improve vigor., stress can be assessed by POMS or POMS 2. The composition for relieving stress according to the present technology can be used for pharmaceutical compositions and food and drink compositions.

A composition for relieving stress comprising a Bifidobacterium breve MCC 1274 (FERMBP-11175) as an active ingredient is provided. The composition for relieving stress according to the present technology can improve or prevent stress-induced anger, confusion, tension, or fatigue, or can improve vigor., stress can be assessed by POMS or POMS 2. The composition for relieving stress according to the present technology can be used for pharmaceutical compositions and food and drink compositions.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.

Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a reduction in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.

A fermented infant formula for promoting improved eating behaviour and reducing the risk of obesity. The formula comprises 3 to 7 g lipid/100 kcal, 1.25 to 5 g protein/100 kcal and 6 to 18 g digestible carbohydrate/100 kcal and wherein the nutritional composition comprises an ingredient fermented by lactic acid producing bacteria, and 0.05 to 1.5 wt % lactic acid based on dry weight.